Innovation Pharmaceuticals Inc (IPIX)

[Lemoncat]

There was nothing misleading about the 200mg arm aside from the results. It was a small sample and performed stronger than the other arms, particularly in the moderate disease sub group analysis.

This led the company to pursue a higher dosage, against moderate-severe disease with a more forgiving metric (PASI vs IGA) in a phase e.g. to further explore those sub group results.

Apparently none of the arms in the phase 2b matched what was seen in the 200mg arm of the way trial. It seems we were the victim of bad luck with a small sample size or overly optimistic subgroup analysis.

Bottom line, 200mg looked successful in 2a. Stronger dosages against large numbers of patients did not confirm. It is very unfortunate but happens all the time.

As for BTD on B-OM: my guess is our sub group analysis resulted in too small a patient sample size. We will never know the actual reason.